在线日韩日本国产亚洲丨少妇伦子伦情品无吗丨欧美性猛交xxxx免费看蜜桃丨精品人妻系列无码一区二区三区丨亚洲精品无码不卡在线播放

Your Good Partner in Biology Research

GLA Recombinant Monoclonal Antibody

  • 中文名稱:
    GLA重組抗體
  • 貨號:
    CSB-RA950991A0HU
  • 規格:
    ¥1320
  • 圖片:
    • IHC image of CSB-RA950991A0HU diluted at 1:100 and staining in paraffin-embedded human rectal cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a Goat anti-rabbit polymer IgG labeled by HRP and visualized using 0.14% DAB.
    • Overlay Peak curve showing Hela cells stained with CSB-RA950991A0HU (red line) at 1:50. The cells were fixed in 4% formaldehyde and permeated by 0.2% TritonX-100. Then 10% normal goat serum to block non-specific protein-protein interactions followed by the antibody (1μg/1*106cells) for 45min at 4℃. The secondary antibody used was FITC-conjugated Goat Anti-rabbit IgG(H+L) at 1:200 dilution for 35min at 4℃.Control antibody (green line) was rabbit IgG (1μg/1*106cells) used under the same conditions. Acquisition of >10,000 events was performed.
  • 其他:

產品詳情

  • 產品描述:
    CSB-RA950991A0HU GLA重組單克隆抗體是針對α-半乳糖苷酶A(GLA)靶點開發的高特異性科研試劑,適用于ELISA、免疫組化(IHC)和流式細胞術(FC)等多種實驗場景。該抗體識別的GLA蛋白是溶酶體糖鞘脂代謝的關鍵酶,其功能異常與法布里病等遺傳代謝性疾病密切相關,為相關疾病機制研究提供重要工具。經多平臺驗證,該抗體在IHC應用中可清晰顯示組織切片中GLA蛋白的亞細胞定位,推薦使用稀釋比例為1:50-1:200;在FC實驗中能有效標記細胞表面及胞內GLA抗原,同等稀釋范圍內呈現優異的信噪比特性。其重組單克隆特性保障了批次間的高度一致性,適用于酶活性調控研究、疾病模型驗證及溶酶體功能分析等科研領域,尤其為代謝途徑探索、病理標志物檢測和藥物靶點篩選提供可靠支持。本產品經嚴格質控,確保低內毒素及高批間穩定性,滿足細胞實驗、蛋白質互作分析等精細化研究需求。
  • Uniprot No.:
  • 基因名:
  • 別名:
    Alpha-galactosidase A (EC 3.2.1.22) (Alpha-D-galactosidase A) (Alpha-D-galactoside galactohydrolase) (Melibiase) (Agalsidase), GLA
  • 反應種屬:
    Human
  • 免疫原:
    A synthesized peptide derived from Human GLA
  • 免疫原種屬:
    Homo sapiens (Human)
  • 標記方式:
    Non-conjugated
  • 克隆類型:
    Monoclonal
  • 抗體亞型:
    Rabbit IgG
  • 純化方式:
    Affinity-chromatography
  • 克隆號:
    30H11
  • 濃度:
    It differs from different batches. Please contact us to confirm it.
  • 保存緩沖液:
    Rabbit IgG in 10mM phosphate buffered saline , pH 7.4, 150mM sodium chloride, 0.05% BSA, 0.02% sodium azide and 50% glycerol.
  • 產品提供形式:
    Liquid
  • 應用范圍:
    ELISA, IHC, FC
  • 推薦稀釋比:
    Application Recommended Dilution
    IHC 1:50-1:200
    FC 1:50-1:200
  • Protocols:
  • 儲存條件:
    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
  • 貨期:
    Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
  • 用途:
    For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

  • 功能:
    Catalyzes the hydrolysis of glycosphingolipids and participates in their degradation in the lysosome.
  • 基因功能參考文獻:
    1. GLA variants found included R118C (n = 2), D83N, and D313Y (n = 7); IVS6-22 C>T, IVS4-16 A>G, IVS2+990C>A, 5'UTR-10 C>T (n = 4), IVS1-581 C>T, IVS1-1238 G>A, 5'UTR-30 G>A, IVS2+590C>T, IVS0-12 G>A, IVS4+68A>G, IVS0-10 C>T, IVS2-81-77delCAGCC, IVS2-77delC. We found that patients with common heart disease did not contain a substantial number of patients with undiagnosed Fabry disease. PMID: 29227985
    2. GLA DNA screening protocols starting from the dialysis population and upstream extended to families of affected individuals may be an effective strategy to maximize the early identification of subjects with Fabry disease. PMID: 30099469
    3. family study with the classical phenotype of Fabry disease due to the novel nonsense mutation c.607G>T (p.E203X) of the GLA gene; the Fabry disease phenotype is highly variable in heterozygote females, even within the same family PMID: 28152533
    4. It negatively regulates calcification of human aortic valve interstitial cells. PMID: 29653899
    5. Results from a study on gene variability markers in early-stage human embryos shows that GLA is a putative variability marker for the 3-day, 8-cell embryo stage. PMID: 26288249
    6. Presence of isolated heterozygous -10C >T SNP is not associated with clinically relevant symptoms or organ manifestations as seen in Fabry disease. PMID: 29794742
    7. The D313Y variant in the GLA gene was not Fabry disease causative in 2 Danish families. PMID: 29037082
    8. The mutation p.D313Y in the GLA gene may lead to organ manifestations and elevation of the Fabry-specific biomarker lyso-globotriaosylsphingosine. PMID: 28276057
    9. Four novel GLA pathogenic mutations are reported and evidence of pathogenicity of the D313Y mutation is provided. PMID: 28988177
    10. alpha-Galactosidase A genotype N215S does not lead to the development of a classical Fabry phenotype but induces a specific cardiac variant of Fabry disease mimicking nonobstructive hypertrophic cardiomyopathy. PMID: 29018006
    11. GLA c.196G>C variant is a genetic risk factor for cerebral small-vessel occlusion and non-cardioembolism in Japanese males but not in females. PMID: 28275245
    12. we presented the clinical characters of a Chinese FD pedigree mimicking familial episodic pain. Furthermore, our finding suggests that a novel double mutation of GLA (c.273_276del TGAT in cis with c.281G>T) is associated with FD PMID: 27531472
    13. Results showed that most Fabry disease patients carrying GLA IVS4+919A did not show abnormal cardiac phenotypes. The near-absence of GLA IVS4+919A in heart disease cohort suggested that this variant is not a frequent cause of overt heart diseases in Taiwan. PMID: 28377241
    14. This longitudinal Fabry Registry study analyzed data from patients with Fabry disease to determine the incidence and type of severe clinical events following initiation of enzyme replacement therapy (ERT) with agalsidase beta, as well as risk factors associated with occurrence of these events PMID: 27510433
    15. alpha-galactosidase A mutation, IVS4-type Fabry disease has features similar to those of classic Fabry disease and a higher frequency of deep white matter hyperintensities and a higher incidence of infarctions and pulvinar signs than in healthy controls PMID: 26869469
    16. We demonstrate that the wild-type sequence harbors an hnRNP A1 and hnRNP A2/B1-binding exonic splicing silencer (ESS) overlapping the 5'splice site (5'ss) that prevents pseudoexon inclusion.we demonstrate that splice switching oligonucleotide (SSO) mediated blocking of the pseudoexon 3'ss and 5'ss effectively restores normal GLA splicing PMID: 27595546
    17. Four patients had non-amenable mutant forms of a-Gal based on the validated cell-based assay conducted after treatment initiation and were excluded from primary efficacy analyses only. PMID: 27834756
    18. Mesenchymal stem cells with reduced GLA activity are prone to apoptosis and senescence due to impaired autophagy and DNA repair capacity. PMID: 28098348
    19. we review the various types of GLA variants and recommend that pathogenicity be considered only when associated with elevated globotriaosylceramide in disease-relevant organs and tissues as analyzed by mass spectrometry. PMID: 27195818
    20. findings revealed the alternative splicing mechanism of GLA (IVS4+919G>A), and a potential treatment for this specific genetic type of Fabry disease by amiloride in the future PMID: 28430823
    21. Results found a novel heterozygous stop codon mutation in exon 1 of the GLA gene in female patients with Fabry Disease with methylation in the non-mutated allele thought to be associated with the clinical severity of the disease. PMID: 28087245
    22. Study described the demographic data, wide clinical spectrum of phenotypes, and GLA mutation spectrum of Fabry disease in Korea. Most of the patients had classical Fabry disease, with a 4 times higher incidence than that of late-onset Fabry disease, indicating an underdiagnosis of mild, late-onset Fabry disease. PMID: 28723748
    23. we reviewed other small molecules that were reported to have a stabilizing effect on some GLA missense mutations in vitro and might be developed to act in synergy or as an alternative to 1-deoxygalactonojirimycin PMID: 27916943
    24. No pathogenic mutations in the coding regions of the GLA gene were identified in this group of patients and thus no Fabry disease was found in this study. PMID: 26981927
    25. High desphospho-uncarboxylated matrix Gla protein level, reflecting a poor vitamin K status, seems to be associated with kidney damage and may be also a marker of cardiovascular risk in CKD patients PMID: 27100101
    26. Similar central nervous system manifestations in patients with the IVS4 mutation or classical Fabry mutations. PMID: 28166746
    27. Case Report: Kidney transplantation from a mother with unrecognized Fabry disease to her son with low alpha-galactosidase A activity. PMID: 26971403
    28. p.M187R GLA mutation in Fabry disease causes a severe systemic and ophthalmologic phenotype, in both male and female patients. PMID: 28225726
    29. The results of the current study suggest that the GLA haplotype D313Y does not lead to severe organ manifestations as seen in genotypes known to be causal for classical Fabry disease. PMID: 27059467
    30. We report a case of Fabry disease with a p.R301X (c.901 C>T) mutation in a 39-year-old man who was being treated for chronic sclerosing glomerulonephritis for 2 years. Family screening tests showed that the proband's mother, sister, and daughter had the same mutation with different phenotypes. PMID: 27156739
    31. Case Report: hypertrophic obstructive cardiomyopathy with Fabry disease with the GLA E66Q mutation. PMID: 27160240
    32. We conclude that a mild GLA variant is typically characterized by high residual enzyme activity and normal biomarker levels. We found evidence that these variants can still be classified as a distinctive, but milder, sub-type of FD. PMID: 26415523
    33. Fabry disease, an X-linked disorder of glycosphingolipids that is caused by mutations of the GLA gene that codes for alpha-galactosidase A, leads to dysfunction of many cell types and includes a systemic vasculopathy. PMID: 26564084
    34. Study describes 5 novel mutations found in the GLA gene of patients with clinical diagnosis of Fabry disease. PMID: 26691501
    35. The present study confirms the heterogeneity of mutations in Fabry disease and the importance of molecular analysis for genetic counseling, female heterozygotes detection as well as therapeutic decisions. PMID: 26297554
    36. GLA gene variations correlate with globotriaosylceramide and globotriaosylsphingosine analog levels in urine and plasma PMID: 26070511
    37. results directly implicated the GLA mutation p.E66Q as the genetic etiology of the Chinese renal variant FD pedigree. PMID: 26456105
    38. This study indicated that the p.E66Q variant of GLA does not affect the progression of chronic kidney disease. PMID: 24718812
    39. Thus, inheritance of the CIH caused an mRNA deregulation altering the GLA expression pattern, producing a tissue glycolipid storage. PMID: 26334996
    40. data strongly suggest that the GLA p.(Arg118Cys) variant does not segregate with Fabry disease clinical phenotypes in a Mendelian fashion, but might be a modulator of the multifactorial risk of cerebrovascular disease PMID: 25468652
    41. In Fabry disease patients, the alpha-galactosidase A-10T allele appears to be causal for neurological manifestations. PMID: 25423912
    42. Some clinical cases of some members of a Sicilian family to express phenotypical variability of Anderson-Fabry disease in subjects with the same genetic mutation in alpha galactosidase A gene, are reported. PMID: 25281798
    43. Case Report: immunohistologically detected synaptopodin upregulation in foamy podocytes in Fabry disease due to novel alpha-galactosidase A mutation. PMID: 25295576
    44. These data confirmed that the specific approach can effectively contribute to the identification of pathological mutations in GLA. PMID: 25382311
    45. The novel mutation p.M187R/g7219 T>G is associated with a particularly malignant cardiac phenotype in males and females over 40 years. PMID: 24679964
    46. OC follows a gene duplication strategy while MGP variability was obtained mostly by the use of multiple promoters and alternative splicing, leading to proteins with additional functional characteristics and alternative gene regulatory pathways. [review] PMID: 25068814
    47. It is clear that a certain intronic haplotype in males with cryptogenic stroke is associated with reduced GLA expression and function. PMID: 25101867
    48. GLA p.E66Q mutation is a genetic risk factor for cerebral small-vessel occlusion in elderly Japanese PMID: 23724928
    49. residues important for expression of the GLA activity PMID: 24386359
    50. A Fabry disease patient and his daughter had the mutation c.493 G > C in the 3d exon of the GLA gene. D165H substitution affects protein folding. This highly conserved AA may be a key amino acid for enzyme functionality. PMID: 24398019

    顯示更多

    收起更多

  • 相關疾病:
    Fabry disease (FD)
  • 亞細胞定位:
    Lysosome.
  • 蛋白家族:
    Glycosyl hydrolase 27 family
  • 數據庫鏈接:

    HGNC: 4296

    OMIM: 300644

    KEGG: hsa:2717

    STRING: 9606.ENSP00000218516

    UniGene: Hs.69089



主站蜘蛛池模板: 精品一区二区久久久久久久网站 | 欧洲精品va无码一区二区三区 | 成视频年人黄网站免费视频| 成人免费777777被爆出| 成年无码动漫av片在线观看羞羞| 久久精品成人免费观看| 男人靠女人的免费视频| 99久久婷婷国产综合精品青草免费| 两根大肉大捧一进一出好爽视频| 天天做天天爱天天要天天| 人人狠狠综合久久亚洲爱咲 | 免费国产在线一区二区| 国产亚洲精品一区二三区| 中文字幕一精品亚洲无线一区| 国模无码视频一区| 久久精品国产第一区二区三区| 高清国产在线拍揄自揄视频| 亚洲国产精品综合久久20| 99久久综合狠狠综合久久 | 国内精品久久久久影院一蜜桃| 国产乱国产乱老熟300部视频| 久久精品99av高久久精品| 丰满无码人妻热妇无码区| 国产精品久久久久9999| 成人网站免费观看| 成人网站色52色在线观看| 三级特黄60分钟在线观看| 92国产精品午夜福利| 在线观看国产成人av片| 免费无遮挡在线观看网站| 国产精品久久久久aaaa| 国产精品无码无在线观看| 久久久av男人的天堂| 欧美xxxx欧美精品| 亚洲精品久久久中文字幕痴女| 亚洲欧美日韩中文字幕在线一区| 亚洲午夜精品a片一区二区app| 久久婷婷五月综合色国产| 日韩 无码 偷拍 中文字幕 | 国产香蕉尹人在线视频你懂的| 肉色丝袜足j视频国产|